This significant increase in short interest suggests that there may be a significant amount of bearish sentiment surrounding the stock. The company’s stock price has been relatively stable in recent months, hovering around $10.00 per share. However, the recent surge in short interest could indicate a potential catalyst for a price decline. STRATA Skin Sciences, Inc.
Get STRATA Skin Sciences alerts: STRATA Skin Sciences (NASDAQ:SSKN – Get Free Report) last announced its quarterly earnings results on Wednesday, August 14th. The medical device company reported ($0.03) earnings per share (EPS) for the quarter. The company had revenue of $8.44 million during the quarter. STRATA Skin Sciences had a negative net margin of 25.40% and a negative return on equity of 50.45%. On average, analysts predict that STRATA Skin Sciences will post -1 EPS for the current fiscal year. Insider Buying and Selling at STRATA Skin Sciences Hedge Funds Weigh In On STRATA Skin Sciences In related news, Director Uri Geiger bought 230,573 shares of STRATA Skin Sciences stock in a transaction dated Monday, July 15th. The shares were acquired at an average cost of $3.14 per share, with a total value of $723,999.22. Following the completion of the transaction, the director now owns 1,441,835 shares in the company, valued at approximately $4,527,361.90. The purchase was disclosed in a filing with the SEC, which can be accessed through this link . In other news, Director Uri Geiger bought 230,573 shares of the stock in a transaction on Monday, July 15th. The stock was acquired at an average cost of $3.14 per share, for a total transaction of $723,999.22. Following the acquisition, the director now owns 1,441,835 shares of the company’s stock, valued at $4,527,361.90. The acquisition was disclosed in a document filed with the SEC, which can be accessed through the SEC website . Also, CEO Dolev Rafaeli purchased 19,100 shares of the business’s stock in a transaction dated Monday, July 15th. The shares were purchased at an average price of $3.14 per share, for a total transaction of $59,974.00. Following the purchase, the chief executive officer now owns 143,156 shares of the company’s stock, valued at approximately $449,509.84. The disclosure for this purchase can be found here . 40.43% of the stock is owned by corporate insiders.
by 100%. This is a significant development in the hedge fund landscape, signifying a potential shift in the investment strategy of one of the leading players in the financial markets. ## Azzad Asset Management Inc. ADV: A Rising Star in the Hedge Fund World? Azzad Asset Management Inc. (ADV) is a relatively new player in the hedge fund world, but its recent actions are raising eyebrows in the stock market.
(Get Free Report) STRATA Skin Sciences, Inc, a medical technology company, develops, commercializes, and markets products for the treatment of dermatologic conditions in the United States, Europe, the Middle East, Asia, Australia, South Africa, and Central and South America. The company operates in two segments, Dermatology Recurring Procedures and Dermatology Procedures Equipment. See Also Receive News & Ratings for STRATA Skin Sciences Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for STRATA Skin Sciences and related companies with MarketBeat.com’s FREE daily email newsletter.
news is a contributor at WhySkin. We are committed to providing well-researched, accurate, and valuable content to our readers.
